Aberdeen Group’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.21M | Buy |
228,746
+14,886
| +7% | +$534K | 0.01% | 641 |
|
|
2025
Q1 | $6.59M | Buy |
213,860
+124,193
| +139% | +$3.83M | 0.01% | 648 |
|
|
2024
Q4 | $2.28M | Sell |
89,667
-14,685
| -14% | -$373K | ﹤0.01% | 751 |
|
|
2024
Q3 | $2.93M | Sell |
104,352
-1,083,657
| -91% | -$30.4M | 0.01% | 732 |
|
|
2024
Q2 | $31.3M | Sell |
1,188,009
-110,391
| -9% | -$2.91M | 0.06% | 284 |
|
|
2024
Q1 | $39.4M | Buy |
1,298,400
+41,032
| +3% | +$1.25M | 0.08% | 249 |
|
|
2023
Q4 | $35.3M | Sell |
1,257,368
-2,448,301
| -66% | -$68.8M | 0.08% | 265 |
|
|
2023
Q3 | $101M | Sell |
3,705,669
-169,484
| -4% | -$4.6M | 0.26% | 91 |
|
|
2023
Q2 | $119M | Sell |
3,875,153
-103,262
| -3% | -$3.17M | 0.28% | 86 |
|
|
2023
Q1 | $143M | Buy |
3,978,415
+460,938
| +13% | +$16.6M | 0.36% | 63 |
|
|
2022
Q4 | $139M | Buy |
3,517,477
+83,405
| +2% | +$3.3M | 0.38% | 63 |
|
|
2022
Q3 | $138M | Sell |
3,434,072
-132,822
| -4% | -$5.34M | 0.41% | 56 |
|
|
2022
Q2 | $150M | Buy |
3,566,894
+1,327,764
| +59% | +$55.8M | 0.47% | 51 |
|
|
2022
Q1 | $87.5M | Sell |
2,239,130
-46,769
| -2% | -$1.83M | 0.22% | 101 |
|
|
2021
Q4 | $91.1M | Buy |
2,285,899
+484,754
| +27% | +$19.3M | 0.2% | 117 |
|
|
2021
Q3 | $65.1M | Sell |
1,801,145
-82,866
| -4% | -$2.99M | 0.15% | 145 |
|
|
2021
Q2 | $77.2M | Buy |
1,884,011
+1,855,388
| +6,482% | +$76.1M | 0.17% | 122 |
|
|
2021
Q1 | $1.25M | Buy |
28,623
+18,420
| +181% | +$803K | ﹤0.01% | 832 |
|
|
2020
Q4 | $510K | Buy |
+10,203
| New | +$510K | ﹤0.01% | 882 |
|